Literature DB >> 12676115

Transitioning the paediatric IBD patient to adult care.

Barbara Désir1, Ernest G Seidman.   

Abstract

Transitioning an adolescent patient to an internist/gastroenterologist's care requires an understanding of the specific issues and challenges involved in the diagnosis and management of paediatric inflammatory bowel disease (IBD). Even though diagnostic criteria, as well as methods are the same in children and adults, younger patients may experience more insidious presentations. A high level of suspicion is necessary for an early and accurate diagnosis. Management of IBD in the paediatric population begins with the assessment of disease extent and activity as well as the identification of potentially serious complications (such as malnutrition, growth/sexual retardation and osteoporosis), which are often present at the time of diagnosis. Treatment includes not only medical, nutritional or surgical therapy but also a multidisciplinary or holistic approach taking into consideration the psychological as well as social impact of the disease on the patient and family.

Entities:  

Mesh:

Year:  2003        PMID: 12676115     DOI: 10.1016/s1521-6918(02)00145-2

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  3 in total

Review 1.  Transition of children with inflammatory bowel disease: big task, little evidence.

Authors:  Wael El-Matary
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

2.  Factitious Disorder in Crohn's Disease: Recurrent Pancytopenia Caused by Surreptitious Ingestion of 6-Mercaptopurine.

Authors:  Allon Kahn; Erika S Boroff; Kari A Martin; Donald W Northfelt; Russell I Heigh
Journal:  Case Rep Gastroenterol       Date:  2015-05-07

3.  Evaluating outpatient transition clinics: a mixed-methods study protocol.

Authors:  Jane N T Sattoe; Mariëlle A C Peeters; Sander R Hilberink; Erwin Ista; AnneLoes van Staa
Journal:  BMJ Open       Date:  2016-08-26       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.